Literature DB >> 17132935

Inhibition of HIV-1 replication by siRNA targeting conserved regions of gag/pol.

Kevin V Morris1, Chris H Chung, Werner Witke, David J Looney.   

Abstract

Short interfering RNAs (siRNAs) targeting HIV-1gag, vif, tat, rev and host CD4 and CCR5 have been reported to inhibit HIV replication. However, the sequence divergence of HIV and the concentration dependence of siRNA activity represent significant challenges to RNAi mediated inhibition. To determine the parameters of RNAi in suppression of HIV-1 we screened seven siRNA candidates targeting highly conserved regions of gag/pol, based on target site GC content, for antiviral activity at varying concentrations. Only two of these inhibited CA-p24 production more than 50%, 2064 and 2161. Activity varied with concentration, with 100 nM producing optimal suppression. Requirements for target sequence conservation and activity over a range of concentrations may severely limit the number of siRNA candidates for therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17132935     DOI: 10.4161/rna.2.1.1198

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  10 in total

1.  Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression.

Authors:  Anne-Marie W Turner; Justin De La Cruz; Kevin V Morris
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

2.  HIV-1 gp120-mediated increases in IL-8 production in astrocytes are mediated through the NF-κB pathway and can be silenced by gp120-specific siRNA.

Authors:  Ankit Shah; Anil Kumar
Journal:  J Neuroinflammation       Date:  2010-12-29       Impact factor: 8.322

3.  RNA interference approaches for treatment of HIV-1 infection.

Authors:  Maggie L Bobbin; John C Burnett; John J Rossi
Journal:  Genome Med       Date:  2015-05-28       Impact factor: 11.117

Review 4.  The therapeutic landscape of HIV-1 via genome editing.

Authors:  Alexander Kwarteng; Samuel Terkper Ahuno; Godwin Kwakye-Nuako
Journal:  AIDS Res Ther       Date:  2017-07-14       Impact factor: 2.250

5.  CRISPR-Cas13a Inhibits HIV-1 Infection.

Authors:  Lijuan Yin; Fei Zhao; Hong Sun; Zhen Wang; Yu Huang; Weijun Zhu; Fengwen Xu; Shan Mei; Xiaoman Liu; Di Zhang; Liang Wei; Shan Cen; Siqi Hu; Chen Liang; Fei Guo
Journal:  Mol Ther Nucleic Acids       Date:  2020-06-01       Impact factor: 8.886

6.  Small interfering RNA targeting for infected-cell polypeptide 4 inhibits herpes simplex virus type 1 replication in retinal pigment epithelial cells.

Authors:  Fang Duan; Shiming Ni; Yuhong Nie; Qiang Huang; Kaili Wu
Journal:  Clin Exp Ophthalmol       Date:  2011-10-20       Impact factor: 4.207

Review 7.  Antiviral applications of RNAi.

Authors:  K V Morris; J J Rossi
Journal:  Handb Exp Pharmacol       Date:  2006

Review 8.  Lentiviral-mediated delivery of siRNAs for antiviral therapy.

Authors:  K V Morris; J J Rossi
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

9.  Knockdown of TFIIS by RNA silencing inhibits cancer cell proliferation and induces apoptosis.

Authors:  Kyle Hubbard; Jennifer Catalano; Raj K Puri; Averell Gnatt
Journal:  BMC Cancer       Date:  2008-05-12       Impact factor: 4.430

10.  Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach.

Authors:  Francesca Spanevello; Arianna Calistri; Claudia Del Vecchio; Barbara Mantelli; Chiara Frasson; Giuseppe Basso; Giorgio Palù; Marina Cavazzana; Cristina Parolin
Journal:  Mol Ther Nucleic Acids       Date:  2016-04-19       Impact factor: 10.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.